EDMUND GOSSELIN

Summary

Affiliation: Albany Medical College
Country: USA

Publications

  1. ncbi Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity
    Constantine Bitsaktsis
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York, USA
    Infect Immun 80:1166-80. 2012
  2. ncbi Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain
    Edmund J Gosselin
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    Hum Immunol 66:1039-49. 2005
  3. ncbi Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens
    Edmund J Gosselin
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    Arch Immunol Ther Exp (Warsz) 57:311-23. 2009
  4. ncbi Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis
    Deepak B Rawool
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    J Immunol 180:5548-57. 2008
  5. ncbi Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis
    Constantine Bitsaktsis
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    J Immunol 182:4899-909. 2009
  6. ncbi Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation
    Robert A Jordan
    Transplantation Immunology Laboratory. Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208-3479, USA
    Clin Diagn Lab Immunol 10:339-44. 2003
  7. ncbi Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system
    Elisaveta Adamova
    Center for Immunology and Microbial Disease, MC-151, Albany Medical College, Albany, NY 12208, USA
    Immunol Invest 34:417-29. 2005

Research Grants

  1. Protective Activity of a Multi-Functional Immunogen
    EDMUND GOSSELIN; Fiscal Year: 2007
  2. Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
    EDMUND GOSSELIN; Fiscal Year: 2009
  3. Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
    Edmund J Gosselin; Fiscal Year: 2010

Collaborators

  • D W Metzger
  • Constantine Bitsaktsis
  • Ying Li
  • Deepak B Rawool
  • Diane R Gosselin
  • Nitin V Kurkure
  • Elisaveta Adamova
  • Mark T Preissler
  • Robert A Jordan
  • Susan K Hollingshead
  • Giang Pham
  • Jesus Colino
  • Clifford M Snapper
  • Bibiana V Iglesias
  • Bibiana Iglesias
  • Yili Lin
  • Karen Hale
  • Mary C Walsh
  • Robert F Graziano
  • Jeffrey A Banas

Detail Information

Publications7

  1. ncbi Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity
    Constantine Bitsaktsis
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York, USA
    Infect Immun 80:1166-80. 2012
    ..Immune serum also showed an enhanced bactericidal activity directed against S. pneumoniae that appears to be lactoferrin mediated...
  2. ncbi Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain
    Edmund J Gosselin
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    Hum Immunol 66:1039-49. 2005
    ..tularensis vaccines that use inactivated organisms. In addition, important new knowledge is added to our understanding of the human immune response to F. tularensis LVS...
  3. ncbi Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens
    Edmund J Gosselin
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    Arch Immunol Ther Exp (Warsz) 57:311-23. 2009
    ....
  4. ncbi Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis
    Deepak B Rawool
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    J Immunol 180:5548-57. 2008
    ..tularensis, a category A biothreat agent. In summary, these studies show for the first time the use of FcRs as a highly effective vaccination strategy against a highly virulent mucosal intracellular pathogen...
  5. ncbi Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis
    Constantine Bitsaktsis
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    J Immunol 182:4899-909. 2009
    ..Thus, these data indicate that enhanced Th1 responses can supersede the requirement for anti-F. tularensis-specific IgA. This observation also has important ramifications for vaccine development against this organism...
  6. ncbi Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation
    Robert A Jordan
    Transplantation Immunology Laboratory. Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208-3479, USA
    Clin Diagn Lab Immunol 10:339-44. 2003
    ..In addition, the availability of a recombinant biotinylated human IL-2 will permit the production of a uniform product suitable for diagnostic and clinical application...
  7. ncbi Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system
    Elisaveta Adamova
    Center for Immunology and Microbial Disease, MC-151, Albany Medical College, Albany, NY 12208, USA
    Immunol Invest 34:417-29. 2005
    ..Furthermore, antibody isotype and cytokine responses following immunization with hFcgammaRI-targeted antigen, suggest enhancement of both Th1 and Th2 responses...

Research Grants4

  1. Protective Activity of a Multi-Functional Immunogen
    EDMUND GOSSELIN; Fiscal Year: 2007
    ..Thus, these studies and this vaccine strategy will be applicable to vaccines against a wide variety of pathogens in adult, pediatric, and immunocompromised populations. ..
  2. Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
    EDMUND GOSSELIN; Fiscal Year: 2009
    ....
  3. Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
    Edmund J Gosselin; Fiscal Year: 2010
    ....